A phase II study tests a new drug for patients with advanced thyroid cancer
Thyroid: right lobe, isthmus, left lobe
A phase II trial of CUDC-907, a new drug that may be able to shrink thyroid tumors that have spread or gotten worse, is being tested in metastatic or advanced thyroid cancer. Thyroid cancer is a result of abnormal cell growth in the thyroid, a butterfly-shaped gland located at the front of the neck below the Adam’s apple. Currently, there is no standard or effective treatment for the most aggressive types of thyroid cancer such as anaplastic and poorly differentiated thyroid cancer.
Electron Kebebew, M.D., F.A.C.S., Chief of the Endocrine Oncology Branch, wants to find out whether CUDC-907 can inhibit certain growth signals in thyroid cancer cells and thus shrink thyroid tumors. Dr. Kebebew's team has studied the rare, neglected and fatal types of thyroid cancer for which there is no standard and effective therapy, and this compound was one of the most promising agents in their preclinical studies. The compound also targets genetic alterations that frequently occur in these types of tumors. View more information about this trial.Summary Posted: Sun, 01/01/2017